A double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability, pharmacokinetics, and activity of ISIS 113715 in patients with type 2 diabetes mellitus who have not received prior therapy
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs ISIS 113715 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
- 16 Oct 2007 Status change from in progress to completed.
- 30 Oct 2006 Status change
- 21 Oct 2006 New trial record.